Category Archives: Inside BIO Industry Analysis

RFS: Shifting Focus on to Climate Change

Gas-Can-Spilling-Corn-115x76

Dueling studies highlight focus on climate impacts of renewable fuel standard. In a recent ClimateWire piece, Environment & Energy reporters Tiffany Stecker and Julia Pyper, highlighted two opposing stances on whether or not biofuels contribute to the increase of greenhouse gas emissions. The Environmental Working Group released a study late June that found U.S. EPA’s proposed cut in the amount of ethanol would “prevent 3 million tons of carbon dioxide from entering the atmosphere — the Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Innovation Zone Company Snapshots: Humanetics Corporation

InnovationZone_Logo_SBIR Companies_VERT_lockup

Next month in San Diego at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science foundation (NSF) to host the first-ever BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies. The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the potential for commercialization. Companies are rigorously vetted through the NIH and NSF SBIR review process prior to Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

ARPA-E Innovation Summit Comes to Washington, DC.

arpa-e-logo

The U.S. Department of Energy’s ARPA-E Innovation Summit is scheduled for February 24-26, 2014 in Washington, DC. The Advanced Research Projects Agency-Energy (ARPA-E) funds transformational projects that create entirely new ways to generate, store, and use energy. Since September 2013, ARPA-E has announced almost $125 million in funding for new projects aimed at finding innovative ways to lower the cost and improve the efficiency of energy technologies. “We’re investing in the best people, the best Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

2013 Novel Drug Approvals

Therapeutic-Indications-with-Novel-Drug-Approvals-in-2013-115x76

The FDA approved 24 novel drugs last year by our count, in line with average approvals for the last ten years but down from the decade-high approvals seen in 2012. Our count is a bit lower than the FDA’s count of 27 new approvals, because we did not include imaging agents like Navidea’s Lymphoseek, or reformulations like J&J’s Simponi Aria. 2013 was the first year the breakthrough-designated therapies were approved, with three breakthrough therapies approved: Gilead’s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Dave Thomas

Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting its annual Buy-side Investor Perception Survey and releasing the results at the 16th Annual BIO CEO & Investor Conference in New York, Monday Feb. 10. But as the results are coming in, BIO is hosting the #BIOBuyside Twitter chat Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,